Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108,380,780
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
63,675,444
-
Shares change
-
+345,628
-
Total reported value, excl. options
-
$1,002,225,041
-
Value change
-
+$5,530,098
-
Number of buys
-
65
-
Number of sells
-
-32
-
Price
-
$15.74
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q3 2022
133 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share as of Q3 2022.
Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63,675,444 shares
of 108,380,780 outstanding shares and own 59% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4,810,298 shares), VR Adviser, LLC (4,563,962 shares), RA CAPITAL MANAGEMENT, L.P. (4,398,453 shares), BVF INC/IL (3,976,543 shares), Rock Springs Capital Management LP (3,961,249 shares), WELLINGTON MANAGEMENT GROUP LLP (3,453,853 shares), VANGUARD GROUP INC (2,931,709 shares), Foresite Capital Management IV, LLC (2,808,034 shares), ORBIMED ADVISORS LLC (2,758,434 shares), and COMMODORE CAPITAL LP (2,410,622 shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.